Non-specific antibodies or antibodies of undetermined significance (AUS) often pose problems for a blood bank technologist and physician. It is well known that antibodies can weaken and evanesce over time, thus eluding detection by routine blood bank techniques. Special enhancement techniques exist (eg, ficin treatment); however, they are often underutilized due to concerns over expense. Ficin is known to enhance reactivity caused by antibodies in the ABO, Rh, Kidd, Lewis, I, and P blood group systems, while destroying reactivity of antibodies in the Duffy, and MNS blood group systems. Herein, we discuss our protocol for using ficin treatment to determine the specificity of antibodies that would otherwise be classified as AUS. Of the 97 AUS specimens that were treated with ficin, we were able to identify 25 new alloantibodies that would have otherwise been missed without ficin treatment. Thus, we believe our protocol enhances transfusion safety, while minimizing additional workload and cost.
Although the risk of viral transmission by transfusion has decreased substantially in the past 20 years, other residual risks remain. 1 According to the United States Food and Drug Administration (FDA), the presence of non-ABO alloantibodies ranked as the third-highest cause of transfusion-related mortality nationwide between 2009 and 2014. 2 Typically, alloimmunization follows exposure to blood via pregnancy or transfusion; donor and recipient factors influence its occurrence. 3 However, much remains unknown regarding prevention of alloimmunization and antibody persistence to improve transfusion safety.
Although large transfusion services identify alloantibodies multiple times per day, the greatest concern regards antibodies that may not have been detected. Some clinically significant alloantibodies are difficult to detect because of their evanescent nature or due to the low sensitivity of the testing method. Tormey and Stack 4 demonstrated that nearly 67% of alloantibodies identified at least once in 304 military veterans disappeared within 5 years of formation.
Therefore, a negative antibody screening result does not guarantee that a patient will not develop hemolysis after an allegedly in vitro compatible red blood cell (RBC) transfusion.
For this reason, the transfusion service must maintain transfusion records indefinitely and check for the history of alloantibodies every time a patient returns to the same institution for care. 5 Another confounding factor in pretransfusion testing is interpretation of unexplained agglutination reactions, or antibody of undetermined specificity (AUS), as recently explored by Liu and Grossman. 6 According to the experience of those authors using gel microtubes, AUS was the most common antibody reported, representing 18% of all alloantibodies. In the most recent sample from this patient, AUS was still present, and all clinically significant alloantibodies were, again, ruled out with homozygous cells. However, we elected to test his plasma with ficin-treated reagent cells in gel microtubes, recognizing that this proteolytic enzyme increases the sensitivity of the assay, helping it to identify antibodies to the ABO, Rh, Kidd, Lewis, P, and I antigens while destroying Duffy and MNS systems antigens. To our surprise, the pattern of reactivity revealed 2 clinically significant antibodies: anti-C and anti-e, which are antigens that the patient phenotypically lacked. After this index case, we instituted a laboratory policy whereby all AUS identified in gel microtubes is followed by testing of the specimen in question using ficin-treated cells. This report details the findings of our experience with that policy and the practicality of our approach.
Materials and Methods
The study protocol was reviewed and approved by the Institutional Review Board of UAB (University of Alabama at Birmingham) Hospital. The protocol consisted of a retrospective review of all antibody workups after a positive result via antibody screening from January 2013 through March 2013. Figure 1 shows our routine workflow, which starts with an automated gel method (ID-MTS GEL Test, Ortho Clinical Diagnostics), unless the testing is ordered STAT (from the Latin word statum, meaning "immediately"). For STAT orders, manual testing in gel microtubes is performed. As can be observed in Figure 1 , a ficin-treated panel with the same reagent RBCs as in the original panel reveals a result consistent with AUS. All alloantibodies not previously identified in our laboratory were labeled new in the database. We did not include alloantibodies exclusively identified in a reference laboratory in this analysis.
Data collected from the antibody identification worksheets were entered into an electronic relational database (FileMaker Pro, version 11; FileMaker, Inc.) for analysis.
Results
Among approximately 12,000 antibody screens performed during the study period, 500 (4.2%) yielded positive results in the ID-MTS Gel Test antibody screening ( Figure 2) . After completing the antibody identification workups, we identified 553 alloantibodies in 354 patients (254 females and 100 males; age range, 0 days-103 years [ Figure 1] ). Most of the alloantibodies had been detected previously in our laboratory: almost 20% of the workups (n ¼ 102) revealed AUS before using ficin.
Among the 97 specimens tested with ficin-treated cells, 25 new alloantibodies were identified ( the Rh system. Anti-E was the most common specificity; further, 10 of 51 (19.6%) new anti-E specificities identified during the study period required ficin for identification.
Among the specimens that tested positive for anti-D 
Discussion
By implementing the routine use of ficin panels after detection of AUS, we identified 11% more new clinically significant alloantibodies during the study period. Without ficin-assisted antibody identification, our index patient could have received units of blood that expressed the corresponding antigen(s) because cross matching at the antiglobulin phase could have been compatible. Clarification of the antibody specificity for this patient allowed the transfusion service to issue appropriate antigen-negative units and to document the presence of the antibody for all future transfusions.
In other patients, ficin confirmed the presence of 7 previously known clinically significant alloantibodies. Although antigennegative units would have been cross matched based on historical data from patients, using ficin confirmed that the AUS result was not due to a newly developed or previously unrecognized alloantibody. In addition to the clinically significant alloantibodies, we also identified 3 antibodies to the Lewis antigen. Although traditionally considered to be clinically insignificant, hemolytic transfusion reactions due to Lewis antibodies have been reported. 7, 8 Gel-based methods for pretransfusion testing were introduced in the early 1990s and were found to be at least as sensitive as, and possibly more sensitive than, tubebased methods with enhancing media. Figure 2 Summary of alloantibodies identified. In some cases of antibody of undetermined specificity (AUS), ficin allowed the identification of an alloantibody, but unexplained reactivity persisted. Also, some workups identified more than 1 alloantibody. 13 Although the sensitivity of RBC antibody detection techniques has increased, the specificity of these techniques has decreased. 11, 14 Detection of reactivity that does not correspond to known clinically significant alloantibodies is not uncommon. AUS was the most common reported "alloantibody" in data gathered by Liu and Grossman, 6 representing 18% of the total reported antibodies. Our policy of using ficin-treated panels provides a possible solution to clarify workups with AUS, which is why we describe it in this report.
It is known colloquially that the use of antibody identification panels that use cells treated with proteolytic agents, such as ficin and papain, will enhance the reactivity of certain alloantibodies while decreasing the reactivity of others. Some alloantibodies react only with enzyme-treated cells and have been referred to as enzyme-only alloantibodies. Previous studies 15, 16 have examined the practice of using enzyme treated cells for antibody screening and have concluded that these cells significantly increased workload while providing minimal benefit. This testing strategy requires a second screening method to avoid missing clinically significant alloantibodies of the Duffy and MNS systems; subsequently, the number of panels needed also increases the occurrence of false positive reactions. 15 In addition, there is some evidence that these enzyme-only alloantibodies may not be clinically significant. 16 In contrast to these studies, our approach uses ficin-treated cells to evaluate specimens only from patients with a positive antibody screening result when our standard workup methods yield inconclusive results or AUS. By using this limited approach, we reduced the impact of this change on the overall workload in the laboratory.
In the 500 antibody workups that we performed, we used ficin 19% of the time to resolve AUS. On average, we performed 1.1 ficin panels each day of the study period. Although this technique requires additional quality assurance measures, pretreated commercially available cells have eliminated the need for in-laboratory preparation. Further, the methodology for performing testing in gel microtubes is the same using untreated or ficin-treated reagent cells. Thus, no new training is required before implementing ficin testing.
Disadvantages of routinely incorporating ficin-treated cells into a transfusion service include additional reagent costs and increased workload.
The circumstances at each institution are unique, but the decision to add ficin-treated panels to the testing algorithm may be considered if AUS is routinely encountered. We propose that the use of ficin-treated cells reduces the cost of sending specimens to a reference laboratory, shortens time for antibody identification and, most importantly, increases transfusion safety. LM
